Blotting Innovations is thrilled to announce that we have received a Phase 2 SBIR grant from the National Institutes of Health (NIH) and National Institute for General Medical Sciences (NIGMS). This recognition highlights our commitment to driving innovation and excellence in our field.
With the support of this Phase 2 grant, Blotting Innovations is well-positioned to significantly advance our research initiatives and further develop and commercialize our novel high-throughput western blotting products. This funding presents an exciting opportunity to build upon the achievements made during the Phase 1 grant. It stands as a testament to the technology and the hard work of our co-founders over the past several years since the inception of Blotting Innovations in 2021.
We want to express our sincere appreciation to the NIH/NIGMS and the reviewers for their confidence in our work. We are deeply grateful for this opportunity and look forward to collaborating with our exceptional team and partners as we embark on the next phase of our research journey.
If you are interested in discussing one of our solutions please reach out to us direct at: blotting.innovations.llc@gmail.com